|Articles|January 15, 2007
IND for iCo
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.
Advertisement
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.
iCo-007, for the treatment of eye diseases such as age-related macular degeneration and diabetic retinopathy, is a second generation drug that inhibits the production of c-Raf kinase, an enzyme associated with the development of new blood vessels in the eye.
Isis will receive a milestone payment from iCo based on the IND filing.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Trehalose-hyaluronate combination aids tear film after eyelid surgery
2
Beyond anti-VEGF: The next wave in retinal therapy
3
ZEISS reports early implantations of AT LUCIA Toric 721P IOL in Europe
4
Mulling over options for mitigating severe vision loss from diabetes
5
















